Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis

The effect of different maintenance therapies on outcome after autologous hematopoietic cell transplantation (AHCT) was analyzed in newly diagnosed multiple myeloma (NDMM) patients using global real-world data. NDMM patients transplanted between 2013 and 2017 were selected from the Worldwide Network for Blood and Marrow Transplantation (WBMT) registry. Overall survival (OS) was evaluated as primary and progression-free survival (PFS), non-relapse mortality and relapse/progression incidence as secondary endpoints. Multivariable 6- month landmark analyses were performed using Cox proportional hazards models including random effect for country. Information was available on 8,269 patients with lenalidomide (n=4,148; 50.2%), thalidomide (n=689; 8.3%) or bortezomib (n=726; 8.8%) as maintenance or no maintenance (n=2,706; 32.7%). In the 6-month landmark analysis, OS at 3 years was higher after maintenance with lenalidomide (86%), with thalidomide (80%) and with bortezomib (83%) as compared to no maintenance (79%, p.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-09-17
DOI
https://doi.org/10.3324/haematol.2026.301244
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis

Minako Iida, A. Sureda, Koji Kawamura, Donal P. McLornan et al.
Haematologica
Multiple Myeloma Research and Treatments
article

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis

Minako Iida, A. Sureda, Koji Kawamura, Donal P. McLornan, Meng Lv, Damiano Rondelli, Anita D’Souza, Dietger Niederwieser, Luuk Gras, Shohei Mizuno, Ai Sim Goh, Katherine Clesham, Asmâa Quessar, Francisca Bass, Sebastián Galeano, Eloísa Riva, Nada Hamad, Daniel Neumann, Cristobal Augusto Frutos Ortiz, Mohamed Amine Bekadja, Xavier Cheng-Hong Tsai, Hira Mian, Mickey Boon Chai Koh, Andrew J. Cowan, Wael Saber, Estelle Verburgh, Arleigh McCurdy, Ali Bazarbachi, Bor-Sheng Ko, John Snowden, Noel Estrada-Merly, Christopher Liam, Laurent Garderet, Aloks Srivastava, Linda Koster, Patrick J. Hayden, Mahmoud Aljurf, Yoshihisa Kodera, Yoshiko Atsuta, Ho Kim Wah, Raffaella Cassano, Hiroyuki Takamatsu, Laurien Baaij, Peter Dreger
article en

Abstract

The effect of different maintenance therapies on outcome after autologous hematopoietic cell transplantation (AHCT) was analyzed in newly diagnosed multiple myeloma (NDMM) patients using global real-world data. NDMM patients transplanted between 2013 and 2017 were selected from the Worldwide Network for Blood and Marrow Transplantation (WBMT) registry. Overall survival (OS) was evaluated as primary and progression-free survival (PFS), non-relapse mortality and relapse/progression incidence as secondary endpoints. Multivariable 6- month landmark analyses were performed using Cox proportional hazards models including random effect for country. Information was available on 8,269 patients with lenalidomide (n=4,148; 50.2%), thalidomide (n=689; 8.3%) or bortezomib (n=726; 8.8%) as maintenance or no maintenance (n=2,706; 32.7%). In the 6-month landmark analysis, OS at 3 years was higher after maintenance with lenalidomide (86%), with thalidomide (80%) and with bortezomib (83%) as compared to no maintenance (79%, p.

Haematologica
Kanazawa University (JP), University of Pisa (IT), Hospital Británico (UY), BC Cancer Agency (CA), University College Hospital (GB), Université Oran 1 Ahmed Ben Bella (DZ), Leipzig University of Applied Sciences (DE), Inserm (FR), Aichi Medical University (JP), St George's, University of London (GB), National Taiwan University (TW), Christian Medical College, Vellore (IN), Peking University (CN), Medical College of Wisconsin (US), Heidelberg University (DE), Ottawa Hospital (CA), Hospital Pulau Pinang (MY), King Faisal Specialist Hospital & Research Centre (SA), Sultanah Aminah Hospital (MY), St George’s University Hospitals NHS Foundation Trust (GB), Groote Schuur Hospital (ZA), Sydney Hospital (AU), University of Illinois Chicago (US), Sorbonne Université (FR), St Vincent's Hospital Sydney (AU), Assistance Publique – Hôpitaux de Paris (FR), Hospital del Salvador (CL), European Society for Blood and Marrow Transplantation (NL), St Vincent’s Private Hospital Sydney (AU), Sheffield Teaching Hospitals NHS Foundation Trust (GB), International University of Rabat (MA), Institut Català d'Oncologia (ES), St George's Hospital (GB), Peking University People's Hospital (CN), University of Illinois Hospital & Health Sciences System (US), National Taiwan University Hospital (TW), Centre de Recherche Saint-Antoine (FR), St. James's Hospital (IE), Hospital de Clínicas (UY), The Japanese Data Center for Hematopoietic Cell Transplantation (JP), IPS Central (PY), National Taipei University of Business (TW), University College London (GB), Tottori University (JP), Sunway University (MY), Heidelberg University (US), Leipzig University (DE), McMaster University (CA), American University of Beirut (LB), National Taipei University (TW)
Good health and well-being
Openalex Percentile: Top 11%
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.